Analysis of Commercial Aquaculture Vaccine Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
According to the latest market study by seasoned analysts at Fact.MR, the global commercial aquaculture vaccine market size has been calculated at US$ 305.2 million for 2024 and is projected to expand at a CAGR of 6.7% and reach a size of US$ 584.3 million by 2034-end.
Commercial aquaculture vaccines are formulated to address specific pathogens that commonly affect farmed aquatic organisms. These pathogens include bacteria, viruses, and parasites that lead to diseases detrimental to the health and productivity of the aquaculture stocks.
Different species within aquaculture, such as fish (e.g., salmon, tilapia), shrimp, and mollusks, may require distinct vaccine formulations. Manufacturers are focused on developing vaccines tailored to the unique immunological needs of each species.
Vaccines in aquaculture are administered through various methods, including immersion, injection, or oral delivery, depending on the characteristics of the target species and the nature of the vaccine.
The primary goal of commercial aquaculture vaccines is to prevent diseases rather than treat them after an outbreak. Vaccination helps build immunity in aquatic organisms, reducing the risk of disease transmission and minimizing economic losses associated with mortalities and reduced growth rates.
Supportive regulatory frameworks and respective government initiatives promoting responsible aqua farming are boosting the commercial aquaculture vaccine market growth in North America.
| Report Attributes | Details |
|---|---|
| Commercial Aquaculture Vaccine Market Size (2024E) | US$ 305.2 Million |
| Forecasted Market Value (2034F) | US$ 584.3 Million |
| Global Market Growth Rate (2024 to 2034) | 6.7% CAGR |
| South Korea Market Value (2034F) | US$ 7 Million |
| Subunit Commercial Aquaculture Vaccine Demand Growth (2024 to 2034) | 8.4% CAGR |
| Key Companies Profiled | Hipra; Ceva Sante Animale; Vaxxinova; Zoetis Inc. (PharmaQ); Merck Animal Health; Elanco Animal Health; AquaBounty Technologies; Benchmark Holdings plc; Tecnovax SA; Bluestar Adisseo Co.; Genentech Biotechnology; Hendrix Genetics BV; Nisseiken Co. Ltd.; Europharma AS; Fish Vet Group; Novartis Animal Health; Intervet Inc.; Provaxs Biotek Inc.; Vaki Aquaculture Systems Ltd. |
“Rising Need for Disease Prevention in Large-Scale Aquaculture Operations”
The commercial aquaculture pharmaceutical landscape is undergoing a transformative phase with ongoing research and development efforts aimed at enhancing the efficacy and applicability of vaccines. This commitment to innovation is crucial for addressing the evolving challenges in disease prevention and maintaining the health of aquatic organisms in large-scale aquaculture operations.
Adjuvants play a pivotal role in vaccine formulations by enhancing the body's immune response to the targeted pathogen. Ongoing research efforts are focused on identifying and developing more effective adjuvants specifically tailored for aquatic species. These adjuvants boost the immune response and contribute to the overall efficiency of the vaccine.
Diversity of aquatic species cultivated in commercial aquaculture necessitates species-specific vaccine formulations. Ongoing R&D efforts are directed towards creating vaccines tailored to the unique immunological profiles of different fish, shrimp, and mollusk species. This approach ensures that vaccines provide optimal protection against specific pathogens affecting each species.
“Growing Adoption of Recirculating Aquaculture Systems”
Adoption of recirculating aquaculture systems (RASs) represents a significant shift in the aquaculture industry, and its influence is reverberating across various facets, including disease prevention through the high demand for vaccines. RAS is a sustainable aquaculture practice that involves the use of closed-system setups to cultivate aquatic organisms, offering several environmental and operational advantages.
Unlike traditional open pond systems, RAS allows for meticulous control over water quality parameters, including temperature, oxygen levels, and waste management. These controlled conditions provide an ideal setting for disease prevention strategies, making vaccines a critical component in maintaining the health of the aquatic stocks.
RAS is often employed in intensive aquaculture systems where higher stocking densities are feasible. In such setups, the health management of aquatic organisms becomes paramount. Vaccines play a crucial role in maintaining optimal health and minimizing the impact of stress-related factors that can be exacerbated in intensive production settings
“Lengthy Regulatory Approval Timelines Delaying Vaccine Introduction”
The regulatory approval processes for aquaculture vaccines are characterized by extensive and time-consuming evaluations. From initial preclinical testing to field trials and eventual market authorization, the timelines can extend over several years. Furthermore, the prolonged approval process delays the commercialization of vaccines, hindering timely access to innovative disease-prevention solutions for aquaculture operators.
“High Research and Development Costs”
The intricate regulatory framework necessitates comprehensive research and development efforts to generate the data required for approval submissions. The costs associated with conducting extensive clinical trials and meeting regulatory standards are contributing to the overall financial burden on vaccine manufacturers. For smaller or newer entrants, these high costs can act as a deterrent, limiting their ability to bring innovative vaccines to market.
“Focus on Developing Expertise in Species-specific Aquaculture Vaccines”
Newcomers should differentiate themselves by specializing in species-specific aquaculture vaccines. Focusing on a niche market allows for in-depth understanding and expertise, making it easier to tailor products to the unique needs of customers. Specialization enhances the perceived value of the vaccines and attracts customers seeking precisely targeted solutions.
“Collaboration with Research Institutions to Expand Market Reach”
Building collaborative partnerships with research institutions and universities can provide new entrants with access to cutting-edge research and development capabilities. By leveraging external expertise, new companies can enhance the scientific foundation of their vaccine formulations, potentially leading to innovative and effective solutions that stand out in the market.
Strong emphasis on biosecurity, technological advancements, and high consumption of seafood are collectively driving the commercial aquaculture vaccine demand in the United States, Germany, and Japan.
“Stringent Biosecurity Measures Boosting Demand for Modern Commercial Aquaculture Vaccines”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 42 Million |
| Growth Rate (2024 to 2034) | 7% CAGR |
| Projected Value (2034F) | US$ 83 Million |
The United States is projected to hold 72.2% North American commercial aquaculture vaccine market share by 2034. The United States places a strong emphasis on biosecurity in aquaculture operations. The need to prevent and control diseases is a significant driver boosting the demand for commercial aquaculture vaccines.
Growing consumer awareness and demand for sustainably sourced seafood is further driving the adoption of sustainable aquaculture practices in the United States, thus boosting aquaculture vaccine sales.
“Strong Emphasis on Sustainable and Ethical Food Production”
Germany places a high value on sustainable and ethical food production. Demand for commercial aquaculture vaccines aligns with this focus, as vaccines are instrumental in preventing diseases without resorting to excessive use of antibiotics.
Sustainable aquaculture practices, including the use of vaccines, resonate with German consumers' preferences for responsibly sourced seafood. Germany's robust research and innovation landscape are also contributing to advancements in aquaculture vaccine technologies.
“High Seafood Consumption and Government Support for Aquaculture”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 16 Million |
| Growth Rate (2024 to 2034) | 7.3% CAGR |
| Projected Value (2034F) | US$ 32 Million |
Japan has a longstanding tradition of seafood consumption, and aquaculture plays a crucial role in meeting the demand. With high seafood consumption comes a pressing need for disease prevention in aquaculture operations. Commercial aquaculture vaccines are in demand to ensure a stable and healthy supply of seafood to meet consumer preferences.
The Japanese government is actively supporting the development of the aquaculture industry to reduce dependence on wild-caught fish. This support includes initiatives to enhance disease prevention measures, creating a conducive environment for the adoption of commercial aquaculture vaccines.
As per this new analysis by Fact.MR, a market research and competitive intelligence provider, the increasing demand for inactivated commercial aquaculture vaccines is driven by their safety profile, species-specific formulations, consistent efficacy, and regulatory advantages.
These attributes position inactivated vaccines as a preferred choice for aquaculture operators seeking effective and reliable disease prevention solutions while adhering to high standards of safety and environmental responsibility.
“Inactivated Vaccines Eliminating Live Agent Risks for Reliable Disease Prevention”
| Attribute | Inactivated Commercial Aquaculture Vaccines |
|---|---|
| Segment Value (2024E) | US$ 217.4 Million |
| Growth Rate (2024 to 2034) | 6.4% CAGR |
| Projected Value (2034F) | US$ 404.1 Million |
Inactivated vaccines provide a safe and residue-free alternative, aligning with stringent food safety standards. Inactivated vaccines involve the use of killed pathogens, eliminating the risk of live agents causing unwanted infections or unintended effects in vaccinated aquatic organisms.
This safety aspect is particularly crucial in aquaculture, where concerns about residue presence in seafood products are high. Furthermore, this is also important in closed-system setups, such as RASs, where biosecurity measures are of utmost importance.
Compared to live vaccines, inactivated vaccines often provide a more consistent level of efficacy. The process of inactivation ensures that the vaccine's potency remains stable over time and under various storage conditions. This consistency is essential for reliable disease prevention and management in aquaculture operations.
Leading producers of commercial aquaculture vaccines are strategically diversifying their product portfolios to address a broad spectrum of aquatic species and pathogens. This approach enables them to cater to the diverse needs of aquaculture producers, providing vaccines tailored to specific species and diseases. A comprehensive product range enhances market competitiveness and also allows manufacturers to capture large market shares.
How big is the commercial aquaculture vaccine market?
The global commercial aquaculture vaccine market is estimated at US$ 305.2 million in 2024.
What is the sales value of commercial aquaculture vaccines in Japan?
Sales of commercial aquaculture vaccines are pegged at US$ 16 million for 2024.
What is the demand projection for commercial aquaculture vaccines for 2034?
Global commercial aquaculture vaccine demand is forecasted to reach a valuation of US$ 584.3 million by 2034-end.
At what rate are commercial aquaculture vaccine sales predicted to increase?
Sales of commercial aquaculture vaccines are projected to rise at a CAGR of 6.7% from 2024 to 2034.
Which vaccine type is projected to account for higher demand?
Revenue from inactivated commercial aquaculture vaccines is forecasted to reach US$ 404.1 million by 2034-end.
Who are the key producers of commercial aquaculture vaccines?
Some of the leading companies are Merck & Co., Inc., Hipra, Technovax, and Elanco.
Table 01: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 02: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 03: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 04: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 05: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 06: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration Age Group
Table 07: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
Table 08: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 10: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 11: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 12: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 13: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 14: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 16: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 17: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 18: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 19: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 20: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 22: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 23: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 24: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 25: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 26: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 27: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 28: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 29: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 30: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 02: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 03: Global Market Share Analysis (%), By Vaccine Type, 2024 to 2034
Figure 04: Global Market Y-o-Y Analysis (%), By Vaccine Type, 2024 to 2034
Figure 05: Global Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 06: Global Market Share Analysis (%), By Pathogen, 2024 to 2034
Figure 07: Global Market Y-o-Y Analysis (%), By Pathogen, 2024 to 2034
Figure 08: Global Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 09: Global Market Share Analysis (%), By Species, 2024 to 2034
Figure 10: Global Market Y-o-Y Analysis (%), By Species, 2024 to 2034
Figure 11: Global Market Attractiveness Analysis By Species, 2024 to 2034
Figure 12: Global Market Share Analysis (%), By Route of Administration, 2024 to 2034
Figure 13: Global Market Y-o-Y Analysis (%), By Route of Administration, 2024 to 2034
Figure 14: Global Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 15: Global Market Share Analysis (%), By End User, 2024 to 2034
Figure 16: Global Market Y-o-Y Analysis (%), By End User , 2024 to 2034
Figure 17: Global Market Attractiveness Analysis, By End User, 2024 to 2034
Figure 18: Global Market Share Analysis (%), By Route of Administration Age Group, 2024 to 2034
Figure 19: Global Market Y-o-Y Analysis (%), By Route of Administration Age Group, 2024 to 2034
Figure 20: Global Market Attractiveness Analysis By Route of Administration Age Group, 2024 to 2034
Figure 21: Global Market Share Analysis (%), By Region, 2024 to 2034
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 23: Global Market Attractiveness Analysis, By Region, 2024 to 2034
Figure 24: North America Market Value Share, By Vaccine Type, 2024 (E)
Figure 25: North America Market Value Share, By Speciess 2024 (E)
Figure 26: North America Market Value Share, By Pathogen, 2024 (E)
Figure 27: North America Market Value Share, By Route of Administration, 2024 (E)
Figure 28: North America Market Value Share, By End User, 2024 (E)
Figure 29: North America Market Value Share, By Country, 2024 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 31: North America Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis By Species, 2024 to 2034
Figure 33: North America Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 34: North America Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis By End User, 2024 to 2034
Figure 36: North America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 37: Europe Market Value Share, By Vaccine Type, 2024 (E)
Figure 38: Europe Market Value Share, By Speciess 2024 (E)
Figure 39: Europe Market Value Share, By Pathogen, 2024 (E)
Figure 40: Europe Market Value Share, By Route of Administration, 2024 (E)
Figure 41: Europe Market Value Share, By End User, 2024 (E)
Figure 42: Europe Market Value Share, By Country, 2024 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 44: Europe Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 45: Europe Market Attractiveness Analysis By Species, 2024 to 2034
Figure 46: Europe Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 47: Europe Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 48: Europe Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 49: Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 50: Middle East and Africa Market Value Share, By Vaccine Type, 2024 (E)
Figure 51: Middle East and Africa Market Value Share, By Species, 2024 (E)
Figure 52: Middle East and Africa Market Value Share, By Pathogen, 2024 (E)
Figure 53: Middle East and Africa Market Value Share, By Route of Administration, 2024 (E)
Figure 54: Middle East and Africa Market Value Share, By End User, 2024 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 57: Middle East and Africa Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 58: Middle East and Africa Market Attractiveness Analysis By Species, 2024 to 2034
Figure 59: Middle East and Africa Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 60: Middle East and Africa Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 61: Middle East and Africa Market Attractiveness Analysis By End User, 2024 to 2034
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2024 to 2034
Figure 63: Rest of the World Market Value Share, By Vaccine Type, 2024 (E)
Figure 64: Rest of the World Market Value Share, By Speciess 2024 (E)
Figure 65: Rest of the World Market Value Share, By Pathogen, 2024 (E)
Figure 66: Rest of the World Market Value Share, By Route of Administration, 2024 (E)
Figure 67: Rest of the World Market Value Share, By End User, 2024 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 69: Rest of the World Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 70: Rest of the World Market Attractiveness Analysis By Species, 2024 to 2034
Figure 71: Rest of the World Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 72: Rest of the World Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 73: Rest of the World Market Attractiveness Analysis By End User, 2024 to 2034
Figure 74: United States Market Value Share, By Vaccine Type, 2024 to 2034
Figure 75: United States Market Value Share, By Species, 2024 to 2034
Figure 76: United States Market Value Share, By Pathogen, 2024 to 2034
Figure 77: United States Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 78: United States Market Value Share, By End User, 2024 to 2034
Figure 79: United States Market Value Analysis (US$ Mn), 2024 to 2034
Figure 80: Canada Market Value Share, By Vaccine Type, 2024 to 2034
Figure 81: Canada Market Value Share, By Species, 2024 to 2034
Figure 82: Canada Market Value Share, By Pathogen, 2024 to 2034
Figure 83: Canada Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 84: Canada Market Value Share, By End User, 2024 to 2034
Figure 85: Canada Market Value Analysis (US$ Mn), 2024 to 2034
Figure 86: United Kingdom Market Value Share, By Vaccine Type, 2024 to 2034
Figure 87: United Kingdom Market Value Share, By Species, 2024 to 2034
Figure 88: United Kingdom Market Value Share, By Pathogen, 2024 to 2034
Figure 89: United Kingdom Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 90: United Kingdom Market Value Share, By End User, 2024 to 2034
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2024 to 2034
Figure 92: Germany Market Value Share, By Vaccine Type, 2024 to 2034
Figure 93: Germany Market Value Share, By Species, 2024 to 2034
Figure 94: Germany Market Value Share, By Pathogen, 2024 to 2034
Figure 95: Germany Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 96: Germany Market Value Share, By End User, 2024 to 2034
Figure 97: Germany Market Value Analysis (US$ Mn), 2024 to 2034
Figure 98: France Market Value Share, By Vaccine Type, 2024 to 2034
Figure 99: France Market Value Share, By Species, 2024 to 2034
Figure 100: France Market Value Share, By Pathogen, 2024 to 2034
Figure 101: France. Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 102: France Market Value Share, By End User, 2024 to 2034
Figure 103: France Market Value Analysis (US$ Mn), 2024 to 2034
Figure 104: Italy Market Value Share, By Vaccine Type, 2024 to 2034
Figure 105: Italy Market Value Share, By Species, 2024 to 2034
Figure 106: Italy Market Value Share, By Pathogen, 2024 to 2034
Figure 107: Italy Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 108: Italy Market Value Share, By End User, 2024 to 2034
Figure 109: Italy Market Value Analysis (US$ Mn), 2024 to 2034
Figure 110: Spain Market Value Share, By Vaccine Type, 2024 to 2034
Figure 111: Spain Market Value Share, By Species, 2024 to 2034
Figure 112: Spain Market Value Share, By Pathogen, 2024 to 2034
Figure 113: Spain Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 114: Spain Market Value Share, By End User, 2024 to 2034
Figure 115: Spain Market Value Analysis (US$ Mn), 2024 to 2034
Figure 116: GCC Countries. Market Value Share, By Vaccine Type, 2024 to 2034
Figure 117: GCC Countries Market Value Share, By Species, 2024 to 2034
Figure 118: GCC Countries Market Value Share, By Pathogen, 2024 to 2034
Figure 119: GCC Countries Market Value Share, By Route of Administration, 2024 to 2034
Figure 120: GCC Countries Market Value Share, By End User, 2024 to 2034
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2024 to 2034
Figure 122: South Africa Market Value Share, By Vaccine Type, 2024 to 2034
Figure 123: South Africa Market Value Share, By Species, 2024 to 2034
Figure 124: South Africa Market Value Share, By Pathogen, 2024 to 2034
Figure 125: South Africa Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 126: South Africa Market Value Share, By End User, 2024 to 2034
Figure 127: South Africa Market Value Analysis (US$ Mn), 2024 to 2034
Commercial Aquaculture Vaccine Market